Clinical trials: PME
Lafora Disease
Intravenous VAL-1221 Lafora Expanded Access Protocol
Only qualified physicians treating a Lafora Disease patient may request VAL-1221 Expanded Access treatment under the Parasail Lafora Expanded Access Protocol (LEAP).
- Trial name
- LEAP (NCT05930223)
- Testing
- VAL-1221
- Sponsor
- Parasail, LLC
Unverricht-Lundborg Disease
Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults
The study will compare the efficacy and safety of Brivaracetam with placebo in patients with Unverricht- Lundborg Disease (ULD).
- Trial name
- NCT00368251
- Testing
- BRV 2.5 mg, BRV 25 mg, BRV 50 mg
- Where
- 18 sites in United States, Canada and 6 more
- Volunteers
- 56 people
- Sponsor
- UCB Pharma
Safety and Efficacy of the Lumax 740 ICD Family
Lumax 740 Master Study
The objective of this study is to prove the safety and efficacy of the Lumax 740 ICD family. Primarily, the newly implemented RV/LV Capture Control algorithm is evaluated, which automatically measures the RV/LV threshold and…
- Trial name
- Lumax 740 (NCT01454050)
- Where
- Germany
- Volunteers
- 189 people
- Sponsor
- Biotronik SE & Co. KG
Colorectal Cancer
CAIman 5 Articulating Maryland in coloRECTAL Cancer Surgery
This voluntary study is part of a Post-Market-Surveillance plan to proactively collect clinical data for the use of Caiman 5 articulating Maryland in colorectal surgery under daily clinical routine.
- Trial name
- CAIRECTAL (NCT04175756)
- Testing
- Caiman 5 articulating Maryland
- Where
- Germany
- Volunteers
- 61 people
- Sponsor
- Aesculap AG
ICD Indication
Linox Smart S DX PME/Master Study
The objective of this study is to prove the safety and efficacy of the Linox smart S DX ICD lead.
- Trial name
- NCT01090401
- Testing
- Linox smart S DX
- Where
- Germany
- Volunteers
- 116 people
- Sponsor
- Biotronik SE & Co. KG
Unverricht-Lundborg Disease
Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults
The study will compare the efficacy and safety of brivaracetam with placebo in patients with Unverricht-Lundborg disease.
- Trial name
- NCT00357669
- Testing
- Brivaracetam 25 mg, Brivaracetam 50 mg
- Where
- 13 sites in Finland, France and 5 more
- Volunteers
- 50 people
- Sponsor
- UCB Pharma SA